MICHAL LOTEM;SHOSHANA FRANKENBURG;ABRAHAM RUTENBERG;ARTHUR MACHLENKIN;RONNY UZANA;GALIT EISENBERG;TAMAR PERETZ-YABLONSKY;RONI ENGELSTEIN;Hadasit Medical Research Services and Development Ltd.
发明人:
MICHAL LOTEM,SHOSHANA FRANKENBURG,ABRAHAM RUTENBERG,ARTHUR MACHLENKIN,RONNY UZANA,GALIT EISENBERG,TAMAR PERETZ-YABLONSKY,RONI ENGELSTEIN
申请号：
IL24660716
公开号：
IL246607D0
申请日:
2016.07.05
申请国别(地区):
IL
年份:
2016
代理人:
摘要：
The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
